Bone marrow transplant market to be driven by rising prevalence of leukemia, lymphoma is expected to grow at a CAGR of 5.80% during the forecast period 2023 to 2032

Market Research Future (MRFR) has published a cooked research report on the “Global Bone Marrow Transplant Market” that contains information from 2018 to 2032. The bone marrow transplant market is estimated to register a CAGR of 5.80% from 2023 to 2032.

MRFR recognizes the following companies as the key players in the global bone marrow transplant market— Lonza, Merck KgaA, Sanofi, AllCells, STEMCELL Technologies Inc., Charles River Laboratories, Beike Biotechnology Co. Ltd., FUJIFILM Cellular Dynamics Inc., CORESTEM, Inc., Gamida Cell, Lifeline Cell Technology, Mesoblast Ltd, PromoCell GmbH, and others.

Market Highlights

The global bone marrow transplant market is accounted to register a CAGR of 5.80% during the forecast period and is estimated to reach USD 17.939 billion by 2032.

Recent advances in DNA editing and cord blood banking have resulted in significantly higher transplant outcomes, boosting the bone marrow transplant market. These advances improve donor-recipient compatibility and expand the application of bone marrow transplants. As a result, the medical community is witnessing an increasing amount of bone marrow transplants, with patients improving from more effective and accessible options for therapy, indicating a favorable trend in hematopoietic stem cell transplantation.

Segment Analysis

The global bone marrow transplant market has been segmented based on type, treatment type, and end user.

On the basis of type, the market is segmented into autologous transplant, allogenic transplant, and others. The autologous transplant segment was attributed to holding the largest market share in 2022. Their popularity emerges from the reduced risk of rejection, fewer challenges, and more convenience, making them the favored substitute for particular medical conditions.

Based on treatment type, the global bone marrow transplant market has been segmented into leukemia, lymphoma, myeloma, myelodysplastic syndrome, myeloproliferative disorders, aplastic anemia, solid tumors, sickle cell anemia, thalassemia, and others. The lymphoma segment was expected to hold the largest market share in 2022. Bone marrow transplants are crucial in treating lymphoma, securing a dominant share in the therapeutic landscape.

Based on end users, the global bone marrow transplant market has been segmented into hospitals, multi-specialty clinics, and ambulatory surgical centers. The hospitals segment was expected to hold the largest market share in 2022. Due to specialized expertise and infrastructure, hospitals are primary centers for performing bone marrow transplants, ensuring comprehensive patient care.

Regional Analysis

The global bone marrow transplant market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe Bone Marrow Transplant market comprises Germany, France, the UK, Italy, Spain, and the Rest of Europe. The Bone Marrow Transplant market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia-Pacific. The Rest of the World's bone marrow transplant market comprises the Middle East, Africa, and Latin America.

The North American regional sector maintained the largest market share for bone marrow transplants. The bone marrow transplant industry is dominated by enhanced healthcare infrastructure and significant expenditures in research and development. The region's well-established medical facilities with expertise assist in increasing success rates, which promotes patient trust. Additionally, a strong network of donor registries and growing knowledge of the advantages of bone marrow transplants strengthen North America's dominant position in this sector, ensuring improved patient outcomes and long-term development in the bone marrow transplant industry.

The bone marrow transplant market in European nations is growing rapidly, owing to advances in medical technology, increasing awareness, and improved healthcare infrastructure. The region's commitment to research and development in transplanting hematopoietic stem cells has resulted in higher success rates and lower problems, increasing trust among medical professionals and patients.

The Asia Pacific region's bone marrow transplant market is growing significantly due to increased awareness, improved healthcare infrastructure, and the rising incidences of hematological diseases. Advanced medical facilities and an increasing number of qualified medical professionals enhance the region's capacity to manage more bone marrow transplant cases. Additionally, collaborative efforts in research and development encourage innovation, making bone marrow transplant operations more accessible and supporting the market's rapid growth in Asia Pacific.

Furthermore, the Rest of the World's bone marrow transplant market is divided into the Middle East, Africa, and Latin America. The market in MEA is experiencing rapid growth due to increasing awareness, advancements in healthcare infrastructure, and expanding donor registries. The rising prevalence of hematological disorders and improved access to medical facilities drive the demand for bone marrow transplants in these regions.

Key Findings of the Study

• The global bone marrow transplant market is expected to reach USD 17.939 billion by 2032, at a CAGR of 5.80% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to rising disposable incomes, improving healthcare infrastructure, growing awareness about bone marrow transplants, and increasing government initiatives to support healthcare advancements.


• Based on end user, the hospital segment was attributed to holding the largest market in 2022, with an approximate market share of 70%.


• Lonza, Merck KgaA, Sanofi, AllCells, STEMCELL Technologies Inc., Charles River Laboratories, Beike Biotechnology Co. Ltd., FUJIFILM Cellular Dynamics Inc., CORESTEM, Inc., Gamida Cell, Lifeline Cell Technology, Mesoblast Ltd, PromoCell GmbH, and others.